Renflexis
Renflexis
Generic Name
Renflexis
Mechanism
* Palmitoylethanolamide (PEA)
* An endogenous fatty acid amide that activates the peroxisome‑proliferator‑activated receptor alpha (PPAR‑α) on mast cells and macrophages.
* Inhibits the release of pro‑inflammatory cytokines (IL‑1β, TNF‑α) and chemokines.
* Modulates neuronal excitability by reducing prostaglandin E₂ production and suppressing ectopic firing in damaged nerves.
* Acts as a “quasi‑antagonist” of the endocannabinoid system, thereby dampening neuro‑immune signaling without cannabinoid receptor activation.
Pharmacokinetics
| Parameter | Value (topical) |
| Absorption | Limited systemic uptake (< 2 % of applied dose). Mainly local skin penetration. |
| Distribution | Accumulates in the dermis and sub‑epidermal nerve endings. |
| Metabolism | Hydrolyzed by hepatic fatty acid amide hydrolase (FAAH) only after systemic absorption; negligible in local tissue. |
| Elimination | Primarily via fecal excretion of unchanged PEA; renal clearance minimal. |
| Half‑life | Approximately 6–8 h for local tissue levels; < 1 h systemically. |
| Drug–Drug Interactions | None clinically relevant due to low systemic exposure. |
Indications
* Chronic neuropathic pain
* Diabetic peripheral neuropathy
* Post‑herpetic neuralgia
* Cervical or lumbar radiculopathy
* Peripheral nerve injury pain (e.g., post‑surgical, trauma)
* Adjunct to systemic analgesics for patients with limited tolerability to oral opioids or NSAIDs.
Contraindications
* Contraindications
* Known hypersensitivity to palmitoylethanolamide, excipients, or components of the formulation.
* Active skin infection or dermatologic conditions at the application site.
* Warnings
* Rare reports of mild irritation, burning, or itching; generally self‑limited.
* Not indicated for acute pain or inflammatory conditions requiring rapid systemic relief.
* Use cautiously in patients with severe hepatic impairment (data limited).
Dosing
* Common Regimen – 1–2 sprays (≈ 0.1 mL) per pain area three to four times daily (total of 4–8 sprays per application) for 12–24 h per day.
* Application technique – Gently massage into the skin; allow to dry before covering.
* Duration – At least 4 weeks to assess efficacy; may continue long‑term for maintenance.
* Titration – Start with the lower frequency; increase if pain remains uncontrolled and no adverse skin reactions.
Adverse Effects
| Adverse Effect | Frequency | Comments |
| Local skin irritation | ↑ 5 % | Burning, itching; resolve with dose adjustment. |
| Dry skin / dermatitis | ≤ 3 % | Moisturize prior to application if needed. |
| Transient headache | ≤ 2 % | Usually linked to systemic absorption; watch in hepatic disease. |
| Rare allergic dermatitis | < 1 % | Consider patch testing in high‑risk patients. |
*Serious adverse events* are exceedingly uncommon due to minimal systemic exposure.
Monitoring
* Pain score (VAS/NRS) – at baseline and weekly for the first month, then monthly.
* Skin Assessment – evaluate for erythema, edema, or rash at each visit.
* Liver Function Tests – baseline and at 3 months if used long‑term or in patients with pre‑existing liver disease.
* Concomitant Analgesic Use – monitor for additive effects or opioid‑related adverse events.
Clinical Pearls
- PEA’s lipid‑micelle formulation enhances transdermal penetration, delivering higher local concentrations than oral PEA.
- Non‑opioid mechanism makes Renflexis ideal for opioid‑naïve or opioid‑averse patients, reducing the risk of abuse.
- Quick onset – patients often report relief within 30 minutes to 2 hours, especially for dorsal root ganglion sensitization.
- Safety profile – negligible systemic side effects allow prolonged use (≥ 6 months) without significant toxicity.
- Combination therapy – adding Renflexis to a standard neuropathic regimen (gabapentin or duloxetine) has shown additive pain relief in several case series.
- Patient education – emphasize proper skin hygiene; avoid occlusive dressings unless instructed, to prevent increased absorption and irritation.
- Cost‑efficacy – although more expensive than generic topical NSAIDs, the reduced need for systemic analgesics may lower overall treatment costs.
--
• Key Takeaway:
Renflexis offers a safe, topical, anti‑inflammatory option for chronic neuropathic pain, leveraging endogenous lipid mediators to dampen neuro‑immune signaling with minimal systemic exposure.